NAD+
| Category | Other Peptides |
| Goals | Longevity & Anti-Aging |
| Evidence level | Clinical (precursors raise NAD+; longevity benefit not proven) |
| Legal status | Precursors sold as supplements; IV NAD+ via clinics; NAD+ itself research-grade |
| FDA status | Not an approved drug; FDA confirmed NMN lawful as a supplement (Sep 2025) |
| Half-life | Rapidly turned over; route-dependent PK |
| Routes | Intravenous · Subcutaneous · Oral (usually as precursors) |
| CAS / MW / Formula | 53-84-9 · 663.43 g/mol · C₂₁H₂₇N₇O₁₄P₂ |
| Last reviewed | 2026-06-07 |
In one line
A central cellular coenzyme (not a peptide) essential to energy metabolism, DNA repair, and sirtuin signaling — heavily marketed for longevity, but with limited human evidence that boosting it slows aging.
Evidence at a glance
You can measurably raise blood NAD+ with precursors, and that is well documented. What is not established is that doing so extends lifespan or reverses aging in humans. Expensive IV NAD+ in particular lacks strong outcome evidence. See Evidence Grading Explained and the Disclaimer.
Key Takeaways
- NAD+ is a coenzyme, not a peptide — included here for completeness because it appears constantly in longevity protocols alongside peptides.
- Required for mitochondrial energy production, DNA repair (PARPs), and sirtuin signaling.
- Cellular NAD+ declines with age, which motivates supplementation interest.
- Most evidence is for precursors (NR, NMN) raising NAD+ levels; clinical outcomes for aging are preliminary and often null.
- IV NAD+ is popular and costly (often >$1,000/session) with weak supporting evidence.
What Is It
Not a peptide
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme, not a peptide. It is a dinucleotide built from a nicotinamide base and an adenine base. It is included on this wiki only because it features prominently in longevity and “peptide stack” culture — it does not belong to the peptide drug class.
NAD+ is one of the most fundamental molecules in cell biology: it shuttles electrons in metabolism (as the NAD+/NADH redox pair) and serves as a substrate consumed by enzymes including sirtuins (linked to stress resistance and metabolic regulation) and PARPs (DNA repair). Because direct NAD+ is poorly taken up by cells, supplementation usually relies on precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — or on IV NAD+ administered in clinics.
Mechanism of Action
- Redox cofactor (established) — NAD+/NADH carries electrons through glycolysis, the TCA cycle, and oxidative phosphorylation; essential for ATP production.
- Sirtuin substrate (established biochemistry; uncertain longevity translation) — sirtuins require NAD+; their activity is tied to calorie-restriction-like benefits in model organisms.
- PARP-mediated DNA repair (established) — DNA-damage responses consume NAD+.
- Age-related decline (observational) — tissue NAD+ falls with age; whether restoring it reverses aging phenotypes in humans is unresolved.
Limitations
Raising NAD+ levels is not the same as producing a clinical benefit. Several human trials confirm precursors elevate NAD+ but fail to show the dramatic metabolic or longevity effects seen in animals.
Evidence by Outcome
| Outcome | Evidence | Notes |
|---|---|---|
| Raising blood NAD+ levels | Clinical | NR/NMN reliably increase NAD+; well tolerated |
| Slowing aging / extending lifespan | Anecdotal / Preclinical | No definitive human evidence |
| Metabolic health (glucose, etc.) | Clinical | Mixed; some signals in specific groups, many null |
| Specific conditions (Parkinson’s, PAD, prediabetes) | Clinical | Small, preliminary, not confirmatory |
| IV NAD+ “energy/anti-aging” benefit | Anecdotal | Popular; outcome evidence weak |
Reported Dosing
Not medical advice
Doses below reflect supplement and clinic practice, not validated anti-aging dosing. See Reconstitution & Dosing Math.
| Form / Route | Dose (typical) | Frequency | Notes |
|---|---|---|---|
| Nicotinamide riboside (oral) | ~250–1000 mg/day | Daily | Most-studied NAD+ precursor |
| NMN (oral) | ~250–1000 mg/day | Daily | FDA confirmed lawful as a US supplement (Sep 2025) |
| IV NAD+ | ~250–1000 mg/session | Periodic | Clinic-administered; slow infusion to limit side effects |
| Subcutaneous NAD+ | Reported, variable | Variable | Less common; limited data |
Pharmacokinetics
NAD+ is rapidly turned over intracellularly and is not efficiently taken up intact, which is why precursors are favored for oral dosing. IV NAD+ raises levels acutely but is given as a slow infusion because rapid administration causes discomfort. PK varies widely by route and form. See Half-Life & Pharmacokinetics.
Side Effects & Risks
- Oral precursors (NR/NMN): generally well tolerated in trials; mild GI upset, flushing possible.
- IV NAD+: rapid infusion commonly causes chest tightness, nausea, flushing, cramping; slowing the drip reduces this.
- High-dose niacin-type precursors can cause flushing and, at very high doses, liver-enzyme changes.
- Cost vs. benefit: IV NAD+ is expensive with weak outcome evidence — a financial as much as a safety consideration.
- See Side Effects & Risk Management.
Cycling
No evidence-based cycling protocol exists. Precursors are typically taken continuously; IV sessions are scheduled periodically by clinics. See Cycling.
Stacks It Appears In
- Longevity stacks alongside peptides such as Epitalon, MOTS-c, and SS-31 (community practice; no validated synergy).
- Often combined with resveratrol or other sirtuin-activator supplements in popular protocols.
Comparisons
- vs SS-31 — both pitched for “mitochondrial/energy” support; SS-31 is a targeted peptide drug (approved for one disease), NAD+ is a coenzyme/supplement.
- vs MOTS-c — MOTS-c signals through AMPK; NAD+ is a metabolic cofactor and sirtuin substrate.
Sourcing & Quality
Oral precursors are sold as dietary supplements (variable quality); IV NAD+ is compounded for clinic use; raw NAD+ is research-grade. Apply the same scrutiny as any supplement/compounded product: Sourcing, How to Read a CoA, Red Flags & Scams, Storage & Handling. No vendors are endorsed here.
Legal & Regulatory Status
(As of 2026-06-07.) NAD+ is not an approved drug for anti-aging. Nicotinamide riboside is marketed as a dietary supplement. NMN’s US supplement status was contested after the FDA concluded in late 2022 that NMN was excluded from the dietary-supplement definition (it had earlier been authorized for drug investigation); the FDA reversed that position in two letters dated September 29, 2025, confirming NMN is not excluded and is lawful in dietary supplements — though it remains a New Dietary Ingredient (NDI) subject to premarket notification. IV NAD+ is provided through clinics/compounding, not as an FDA-approved therapy. See Regulatory & Legal Status.
FAQ
Is NAD+ a peptide? No. It is a coenzyme (a dinucleotide). It is listed here only because it is ubiquitous in longevity/peptide protocols.
Will NAD+ make me live longer? There is no definitive human evidence that NAD+ or its precursors extend lifespan or reverse aging, despite promising animal data.
Precursor pills vs IV — which is better? Oral precursors reliably raise NAD+ and are far cheaper; IV NAD+ raises levels acutely but has weak outcome evidence and notable infusion side effects.
Is NMN legal to sell? Yes — as of September 2025 the FDA confirmed NMN is not excluded from the dietary-supplement definition (reversing its 2022 stance), so it is lawful in US supplements, though it remains a New Dietary Ingredient requiring premarket notification. NR has long been marketed as a supplement.
References
- Martens C.R. et al. (2018). “Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults.” Nature Communications. Nature
- Imai S., Guarente L. (2017). “It takes two to tango: NAD+ and sirtuins in aging/longevity control.” PMC. PMC5514996
- NPR (2026). “Marketers say NAD+ pills and infusions can boost longevity. What’s the evidence?”
- CNBC (2025). “NAD+ infusion is the latest trendy anti-aging treatment” — longevity-physician commentary on weak evidence.
- U.S. FDA letters (2025-09-29) reversing the NMN drug-exclusion determination (NMN not excluded from the dietary-supplement definition; remains an NDI). Reported via NutraIngredients/Venable LLP regulatory analysis (2025).
← Other Peptides · Home Educational information only — not medical advice. See Disclaimer.